Ligand validation:6JYC

OLA: OLEIC ACID

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6JYC_OLA_A_304	47%	47%	0.132	0.923	0.95	1.1	1	1	2	0	70%	0.7
6JYC_OLA_A_305	41%	56%	0.166	0.881	0.8	0.88	1	1	2	0	100%	1
6JYC_OLA_A_310	35%	76%	0.111	0.923	0.33	0.6	-	-	0	0	30%	0.3
6JYC_OLA_A_311	30%	70%	0.132	0.893	0.34	0.81	-	-	0	0	45%	0.45
6JYC_OLA_A_309	29%	58%	0.15	0.897	0.98	0.64	1	-	0	0	50%	0.5
6JYC_OLA_A_308	25%	43%	0.123	0.826	1.04	1.15	1	1	0	0	60%	0.6
6JYC_OLA_A_306	22%	53%	0.146	0.781	0.84	0.99	1	2	0	0	90%	0.9
6JYC_OLA_A_313	18%	49%	0.151	0.833	0.71	1.24	-	-	0	0	45%	0.45
6JYC_OLA_A_307	15%	52%	0.156	0.802	0.67	1.17	-	1	1	0	50%	0.5
6JYC_OLA_A_312	9%	48%	0.253	0.845	0.7	1.28	-	1	0	0	45%	0.45
6JYC_OLA_A_314	8%	60%	0.17	0.723	0.81	0.72	1	-	0	0	55%	0.55
5G28_OLA_A_1275	49%	41%	0.083	0.927	1.15	1.14	1	1	1	0	45%	0.45
7CRL_OLA_A_305	49%	39%	0.134	0.878	1	1.39	1	2	1	0	100%	0.7582
7CRJ_OLA_A_305	48%	49%	0.13	0.87	0.9	1.05	1	2	0	0	100%	0.8453
6JY7_OLA_A_304	46%	46%	0.121	0.91	0.95	1.15	1	2	1	0	70%	0.7
6JYB_OLA_A_304	45%	46%	0.119	0.904	0.94	1.15	1	2	1	0	70%	0.7
6DJ6_OLA_B_402	92%	68%	0.081	0.971	0.55	0.69	-	-	0	0	100%	1
1LFO_OLA_A_128	79%	59%	0.097	0.943	0.78	0.79	1	-	0	0	100%	1
8GEW_OLA_A_202	64%	57%	0.138	0.938	0.69	0.94	-	2	0	0	100%	0.44
7V3K_OLA_D_401	55%	65%	0.16	0.928	0.6	0.74	-	-	2	0	100%	1
7KAZ_OLA_B_600	54%	53%	0.126	0.891	0.82	0.99	1	1	0	0	100%	0.87

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.